Home | Structured Search | Drug Resource
Find: within
Anthrax > Diagnosis Author: Sandro Cinti, MD; Barbara Robinson-Dunn, PhD; Niklas Mackler, MD
Editorial changes - 2008-10-10
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools

Rationale:

  • GI anthrax presents as a nonspecific gastrointestinal syndrome with nausea, vomiting, and malaise and progresses rapidly to bloody diarrhea, acute abdomen, or sepsis.
  • Mortality from GI anthrax is very high, and early diagnosis may prevent sickness and death.
  • GI anthrax often occurs concomitantly with inhalational anthrax; therefore, rapid intervention in patients with inhalational anthrax and signs of GI disease is essential.

Evidence:

  • GI anthrax progresses quickly from nausea, vomiting, and malaise to GI bleeding, acute abdomen, and in some cases massive ascites (24; 31; 32).
  • B. anthracis invades the submucosa of the lower GI tract to cause erosions and bleeding. In the Sverdlovsk outbreak, pathologic specimens showed B. anthracis infiltration of the liver and intestinal mucosa. The small intestine contained numerous submucosal hematomas (29; 32).
  • In the Sverdlovsk outbreak of inhalational anthrax, 39 of 42 patients had evidence of GI disease on pathology (29; 33).

Comments:

  • None.

FAQs
Barbara Robinson-Dunn, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Demetrios N. Kyriacou, MD, PhD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Niklas Mackler, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sandro Cinti, MD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.